SK pharmteco

At SK pharmteco, we are committed to sparking waves of change by delivering customer-focused solutions for the pharmaceutical and biopharmaceutical industries. With a global network of cGMP facilities in key strategic locations, we empower our clients to bring therapies to the patients they serve. Want to learn more? We'll be at CPHI Milan and Alliance for Regenerative Medicine's 2024 Cell & Gene Meeting on the Mesa next week talking about how we deliver life-impacting therapies. Stop by our booths: 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗲𝘀𝗮 Phoenix, AZ October 7-9, 2024  Booth #: F13 𝗖𝗣𝗛𝗜 Milan, Italy  October 8-10, 2024 Booth #: 5D33 in hall 5 See you there! 👋 Book a meeting: https://lnkd.in/eAQgsr73 #CPHIMilan #Pharma #Biopharma #CGMesa24 #CellandGeneTherapy #CDMO #networking

𝗦𝗞 𝗽𝗵𝗮𝗿𝗺𝘁𝗲𝗰𝗼 𝗮𝗻𝗱 𝗔𝗮𝘃𝗶𝗚𝗲𝗻 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝘁𝗼 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗲 𝗔𝗮𝘃𝗶𝗚𝗲𝗻’𝘀 𝗟𝗲𝗮𝗱 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗳𝗼𝗿 𝗛𝗲𝗮𝗿𝘁 𝗙𝗮𝗶𝗹𝘂𝗿𝗲 We are excited to share that SK pharmteco has entered into a multi-year partnership with AaviGen GmbH to manufacture their innovative gene therapy product targeting heart failure. This collaboration leverages SK pharmteco’s expertise in viral vector manufacturing to support the development and commercialization of AaviGen’s breakthrough therapy aimed at reversing heart muscle dysfunction.    Patrick Mahieux, President of Cell and Gene, Europe at SK pharmteco, shared: “Our commitment to quality and deep expertise in advanced therapies make us the ideal partner for AaviGen. We are proud to contribute to the advancement of this innovative treatment and help bring hope to heart failure patients worldwide.”   Learn more about this exciting partnership here: https://lnkd.in/e-yNBgDY #GeneTherapy #HeartFailure #AdvancedTherapies #Biopharmaceutical #SKpharmteco #AaviGen #CDMO

Small Molecule Monday Spotlight: Global Network & Specialized Capabilities At SK pharmteco, our global network of five small molecule production facilities across North America, Europe, and Asia guarantees supply chain security, while delivering local and regional support tailored to your unique needs. 🔸 5 production facilities featuring 28 commercial lines, 10 semi-works lines, 17 pilot & kg labs, and 5 R&D centers 🔸 Analytical development & CGMP testing labs 🔸 ~265,000 gallons (~1,000 m³) global production capacity 🔸 34 approved products currently in production 🔸 Specialized Capabilities including our SmartPlatform™ Portfolio as an integrated suite of technologies Discover how SK pharmteco’s vast network can support your small molecule needs: https://lnkd.in/egkutM86 #SmallMolecules #APIs #GlobalInnovation #CDMO #PharmaceuticalManufacturing

𝗦𝗞 𝗽𝗵𝗮𝗿𝗺𝘁𝗲𝗰𝗼 𝗜𝗻𝘃𝗲𝘀𝘁𝘀 $𝟮𝟲𝟬 𝗠𝗶𝗹𝗹𝗶𝗼𝗻 𝘁𝗼 𝗘𝘅𝗽𝗮𝗻𝗱 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝗺𝗮𝗹𝗹 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗲 𝗮𝗻𝗱 𝗣𝗲𝗽𝘁𝗶𝗱𝗲 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 SK pharmteco is proud to announce a $260 million investment to expand our global small molecule and peptide production capabilities in a new state-of-the-art facility in Sejong, South Korea. This expansion reinforces our commitment to delivering cutting-edge CDMO services and providing our partners with unmatched global manufacturing solutions. From new advanced facilities to increased production capacity, we’re enhancing our ability to support the growing demands of the pharmaceutical industry. 𝗪𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗺𝗲𝗮𝗻𝘀: • Increased capacity for small molecules and peptides • Enhanced technological capabilities • Strengthening our global footprint in the CDMO sector Read more: https://lnkd.in/e45tqdr2 #CDMO #PharmaceuticalManufacturing #SmallMolecule #PeptideProduction #GlobalExpansion

Get the scoop on our latest innovations! 🍦 Visit us at booth #5D33 in Hall 5 during CPHI Milan, October 8-10. We’re serving up more than just gelato—let’s chat about the future of biopharmaceutical manufacturing and how our capabilities can support your success. See you there! 👋  https://lnkd.in/e-_2hmKh #CPHIMilan #CDMO #SmallMolecule #CellAndGeneTherapy #AnalyticalServices #Pharma 

Hot off the press! Check out our September newsletter to catch up on all things SK pharmteco and industry insights. Highlights include: • Evaluating drug supply chains in the EU • Upcoming webinar on Control Strategies and Method Development for Nitrosamines in APIs & Drug Products • The Importance of the Cell Line Webinar replay From cutting-edge viral vector manufacturing to breakthrough therapeutic platforms, we’ve got the updates you don’t want to miss. #CDMO #pharmaceuticalmanufacturing #smallmolecules #cellandgenetherapies #analyticaltesting #newsletter

SK pharmteco Partners to Enhance Secure, Robust Sample Management for our Cell & Gene Therapies and Small Molecules customers At SK pharmteco, we are committed to delivering exceptional value and service to our clients. Today, we are proud to announce our partnership with Cryoport Inc., a global leader in life sciences supply chain solutions, that will enhance our ability to support our Cell & Gene Therapy and Small molecule customers with robust sample management solutions for their critical therapies. For our clients, this means: • Increased efficiency in the delivery of therapies to patients • Enhanced supply chain integrity to safeguard product quality and safety • A comprehensive solution, reducing complexity in managing logistics and manufacturing processes Read more: https://lnkd.in/e7GPt7Tw #CellAndGeneTherapy #SmallMolecules #Pharma #Biotech #SKpharmteco #CustomerFocused #SupplyChainExcellence

Cutting down the cost of goods sold (CoGS) is crucial for making advanced therapies accessible. By optimizing areas like media feeds, transfection reagents, lysis buffers, and high-fidelity plasmids, manufacturers can achieve up to 75% cost savings at scale—resulting in millions of dollars saved annually. Discover how strategic raw material improvements are driving affordability in viral manufacturing. Learn more in our latest white paper: https://lnkd.in/eZsw_Cfv #ViralVector #GeneTherapy #Bioprocessing #AAV #CGMP #Innovation #Biotech

🔬 Small Molecule Monday Spotlight: Dublin, Ireland Our facility in Swords, Ireland, recently celebrated 60 years of pharmaceutical excellence. Specializing in small and large-scale API and intermediate manufacturing, this facility offers 97m³ (25,616 US gal) capacity and is specifically designed for API validation and commercial production. In addition, this facility supports large-scale high potency API production (down to 10 ng/m³ containment) and serves as our Global Center of Excellence for material science.   Key Highlights: 🔸25,616 gallons (97 m³) capacity 🔸4 small-scale & 3 large-scale plants 🔸High Potency, Material Science, Analytical Services Want to learn more about our facilities? https://lnkd.in/egkutM86 #SmallMoleculeMonday #Manufacturing #Automation #APIs #SKpharmteco

What an incredible few days at the CAR-TCR Summit Series! It was an honor to be part of such an inspiring event and connect with leaders advancing the field of cell and gene therapy. A special thanks to everyone who joined the SK pharmteco Cell-ebration – it was a great opportunity to share insights, explore collaboration opportunities, and celebrate the progress being made in the industry. Looking forward to staying connected and driving forward this vital mission! #CARTCR #CARTCRSummit #CGT